首页> 美国卫生研究院文献>Cancer Science >Overexpression of natural killer group 2 member D ligands predicts favorable prognosis in cholangiocarcinoma
【2h】

Overexpression of natural killer group 2 member D ligands predicts favorable prognosis in cholangiocarcinoma

机译:自然杀手组2成员D配体的过表达预测胆管癌的预后良好。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The natural killer group 2 member D (NKG2D) receptor and its ligands are important mediators of immune responses to tumors. NKG2D ligands are overexpressed in several malignant tumor types; however, the prognostic value of these ligands is unclear. Here, we aimed to elucidate the role of NKG2D ligands in extrahepatic cholangiocarcinoma (EHCC). We therefore investigated the expression of the NKG2D receptor and its ligands MHC class I chain‐related proteins A and B (MICA/B), unique long 16 binding protein (ULBP) 1, and ULBP2/5/6 in resected specimens from 82 patients with EHCC. All NKG2D ligands were highly expressed in EHCC. High expression of MICA/B or ULBP2/5/6 correlated with overall and disease‐free survival. In contrast, high expression of ULBP1 was significantly associated with improved overall survival, but not disease‐free survival. Concurrent high expression of multiple NKG2D ligands revealed significantly better overall and disease‐free survival than that observed with the overexpression of any one NKG2D ligand. Co‐expression of multiple NKG2D ligands was an independent prognostic indicator of improved survival. Furthermore, co‐overexpression of multiple NKG2D ligands was significantly correlated with high expression of the NKG2D receptor. Inhibiting interactions between multiple NKG2D ligands and the NKG2D receptor might be a promising approach for controlling cancer progression and improving patient prognosis in EHCC.
机译:天然杀伤剂组2成员D(NKG2D)受体及其配体是对肿瘤免疫反应的重要介体。 NKG2D配体在几种恶性肿瘤类型中过表达。然而,这些配体的预后价值尚不清楚。在这里,我们旨在阐明NKG2D配体在肝外胆管癌(EHCC)中的作用。因此,我们调查了82例患者的标本中NKG2D受体及其配体MHC I类链相关蛋白A和B(MICA / B),独特的长16结合蛋白(ULBP)1和ULBP2 / 5/6的表达。与EHCC。所有的NKG2D配体均在EHCC中高度表达。 MICA / B或ULBP2 / 5/6的高表达与总体生存和无病生存有关。相反,ULBP1的高表达与总生存期的改善显着相关,但与无病生存期却没有显着相关。与任何一种NKG2D配体的过表达相比,多种NKG2D配体的同时高表达显示出更好的总体生存率和无病生存期。多种NKG2D配体的共表达是存活率提高的独立预后指标。此外,多种NKG2D配体的共过量表达与NKG2D受体的高表达显着相关。抑制多个NKG2D配体与NKG2D受体之间的相互作用可能是控制EHCC癌症进展和改善患者预后的有前途的方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号